Summary

Overview
Global ambulatory polysomnography systems market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Ambulatory polysomnography systems are portable and lightweight devices, allowing patients to perform sleep tests outside of a typical sleep laboratory or clinical environment, such as in their own homes. Ambulatory polysomnography (Amb-PSG), or type II PSG, allows one to diagnose other sleep comorbidities with the advantage of characterizing sleep stages and measuring arousals, total sleep time (TST) and an accurate respiratory disturbance index (RDI).
Ambulatory polysomnography (PSG) is introduced as a new method for assessing sleep bruxism. Nocturnal recordings of masseter electromyography (EMG), electro-encephalography, electro-oculography, electrocardiography, thoracic effort and body position allow for the detection of typical nocturnal masseter activity as well as the determination of sleep stages.
Market Dynamics: Drivers and Restraints
Rise in the prevalence of obstructive sleep disorders
Approximately 1 billion of the world's population of 7.3 billion people, between the ages of 30 and 69 years, are estimated to have the most common type of sleep-disordered breathing, obstructive sleep apnoea (OSA). OSA prevalence is rising and affects all countries. The increase in prevalence is driven by the global increase in obesity, the major risk factor for OSA.2-6 In this review, we examine contributing factors, the burden of disease, approaches and challenges in addressing the global burden of OSA.
Furthermore, ambulatory polysomnography systems are also driven by various factors like advancements in the systems, strategic partnerships with key players and others to help the market grow during the forecast period.
Market Dynamics: Restraint
The majority of the population, especially in rural regions, is not aware of the serious implications of sleep apnea. If sleep disorders are not treated, they can lead to chronic conditions such as heart failure, stroke, high blood pressure, diabetes and obesity.
This can further lead to severe health conditions such as uncontrolled blood pressure, heart attack, weakened and narrow blood vessels of kidneys, and aneurysms. The lack of awareness about sleeping disorders in a significant chunk of the population is likely to hamper the growth of the ambulatory polysomnography (PSG) systems market shortly.
Segment Analysis
The global ambulatory polysomnography systems market is segmented based on product type, application, end-user and region.
The 12 channels from the product type segment accounted for approximately 43.5% of the ambulatory polysomnography systems market share
The 12 channels from the product type segment accounted for approximately 43.5% and is expected to dominate during the forecast period. Ambulatory PSG systems with up to 12 channels provide a wide range of physiological data, including EEG, EOG, EMG, EMG, EMG, and more, enabling healthcare providers to accurately evaluate a patient's sleep, thereby enhancing their overall patient care.
Furthermore, increased awareness of sleep disorders and their influence on overall wellness has led to a rise in demand for complete sleep tests. The value of precise and complete sleep evaluations is recognised by both patients and medical professionals, which has fueled the growth of up to 12 channel PSG systems segment.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the factors such as lifestyle, obesity, and ageing contributing to a substantial number of individuals affected by conditions like obstructive sleep apnea (OSA), and insomnia among others. The need for accurate diagnosis and treatment drives the demand for ambulatory polysomnography systems in the region.
Furthermore, North America boasts a well-developed healthcare infrastructure, including numerous hospitals, clinics, and sleep centers. These facilities often incorporate ambulatory PSG systems for sleep studies and diagnostics, contributing to the market's size.
For instance, in April 2023, Onera Health, a leader in transforming sleep medicine and remote monitoring, stated an exclusive strategic partnership with MedBridge Healthcare, a leading provider of sleep management services including sleep screening, in-centre, inpatient and home diagnostic testing and therapy coordination.
This new partnership aims to broaden access to Onera’s medical-grade PSG-as-a-Service solution, further improving the patient experience and lowering the operational burden currently faced in many sleep clinics across the US.
Moreover, North America has one of the highest reported prevalence rates of sleep disorders globally. For instance, according to the American Sleep Association [ASA), the average individual received less than seven hours of sleep every night in 2021, and 50 to 70 million individuals in the U.S. were affected by an insomnia disorder.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the market for ambulatory polysomnography (PSG) systems. Initially, the pandemic disrupted the supply chain and healthcare services, leading to a negative impact on the ambulatory polysomnography systems market. However, the pandemic also emphasized the importance of remote healthcare monitoring and diagnostics, leading to a greater focus on telemedicine and home-based care, including ambulatory PSG equipment for remote sleep monitoring.
Market Segmentation
By Product Type
• Up to 12 channels
• Up to 24 channels
• Up to 32 channels
• Above 32 channels
By Application
• Obstructive sleep apnea
• Chronic insomnia
• Narcolepsy
• Others
By End-user
• Hospitals
• Home care settings
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Natus Medical Incorporated, Nihon Kohden Corporation, ResMed Inc, Löwenstein Medical Technology GmbH Co. KG, Neurosoft, Cadwell Industries Inc, Somnomedics Gmbh, Nox Medical, ElectraMed Corporation, Compumedics Limited among others.
Key Developments
 In March 2020, Nox Medical officially launched its innovative polysomnographic system, the Nox A1, in the U.S. and Canada. The Nox A1 is a powerful, ambulatory PSG device that combines thoughtful design with clinical accuracy, allowing sleep labs to maximize their investment with multiple functions in one single device.

Why Purchase the Report?
• To visualize the global ambulatory polysomnography systems market segmentation based on product type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ambulatory polysomnography systems market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global ambulatory polysomnography systems market report would provide approximately 69 tables, 70 figures and 183 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the prevalence of obstructive sleep disorders
4.1.1.2. Rise in the advancements of systems
4.1.2. Restraints
4.1.2.1. High cost associated with the devices
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Up to 12 channels*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Up to 24 channels
7.4. Up to 32 channels
7.5. Above 32 channels
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Obstructive sleep apnea*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chronic insomnia
8.4. Narcolepsy
8.5. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Home care settings
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Natus Medical Incorporated*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Nihon Kohden Corporation
12.3. ResMed Inc
12.4. Löwenstein Medical Technology GmbH Co. KG
12.5. Neurosoft
12.6. Cadwell Industries Inc
12.7. Somnomedics Gmbh
12.8. Nox Medical
12.9. ElectraMed Corporation
12.10. Compumedics Limited
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us